RAD51 is a Poor Prognostic Marker and a Potential Therapeutic Target for Oral Squamous Cell Carcinoma

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2023 Oct 5

PMID 37798649

Authors

Yu-Fen Tsai

Leong-Perng Chan

Yuk-Kwan Chen

Chang-Wei Su

Ching-Wei Hsu

Yen-Yun Wang

Shyng-Shiou F Yuan

Affiliations

Soon will be listed here.

Abstract

Objectives: RAD51 overexpression has been reported to serve as a marker of poor prognosis in several cancer types. This study aimed to survey the role of RAD51 in oral squamous cell carcinoma and whether RAD51 could be a potential therapeutic target.

Materials And Methods: RAD51 protein expression, assessed by immunohistochemical staining, was used to examine associations with survival and clinicopathological profiles of patients with oral squamous cell carcinoma. Lentiviral infection was used to knock down or overexpress RAD51. The influence of RAD51 on the biological profile of oral cancer cells was evaluated. Cell viability and apoptosis after treatment with chemotherapeutic agents and irradiation were analyzed. Co-treatment with chemotherapeutic agents and B02, a RAD51 inhibitor, was used to examine additional cytotoxic effects.

Results: Oral squamous cell carcinoma patients with higher RAD51 expression exhibited worse survival, especially those treated with adjuvant chemotherapy and radiotherapy. RAD51 overexpression promotes resistance to chemotherapy and radiotherapy in oral cancer cells in vitro. Higher tumorsphere formation ability was observed in RAD51 overexpressing oral cancer cells. However, the expression of oral cancer stem cell markers did not change in immunoblotting analysis. Co-treatment with RAD51 inhibitor B02 and cisplatin, compared with cisplatin alone, significantly enhanced cytotoxicity in oral cancer cells.

Conclusion: RAD51 is a poor prognostic marker for oral squamous cell carcinoma. High RAD51 protein expression associates with resistance to chemotherapy and radiotherapy. Addition of B02 significantly increased the cytotoxicity of cisplatin. These findings suggest that RAD51 protein may function as a treatment target for oral cancer.

Trial Registration: Number: KMUHIRB-E(I)-20190009 Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, approved on 20190130, Retrospective registration.

Citing Articles

Photonic Crystal Surface Mode Real-Time Imaging of RAD51 DNA Repair Protein Interaction with the ssDNA Substrate.

Nifontova G, Charlier C, Ayadi N, Fleury F, Karaulov A, Sukhanova A Biosensors (Basel). 2024; 14(1).

PMID: 38248420 PMC: 10813746. DOI: 10.3390/bios14010043.

References

Wu R, Patel A, Tokumaru Y, Asaoka M, Oshi M, Yan L . High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer. Breast Cancer Res Treat. 2022; 193(1):49-63. PMC: 8995390. DOI: 10.1007/s10549-022-06552-0. View

Richardson C . RAD51, genomic stability, and tumorigenesis. Cancer Lett. 2005; 218(2):127-39. DOI: 10.1016/j.canlet.2004.08.009. View

Li Y, Yu H, Luo R, Zhang Y, Zhang M, Wang X . Elevated expression of Rad51 is correlated with decreased survival in resectable esophageal squamous cell carcinoma. J Surg Oncol. 2011; 104(6):617-22. DOI: 10.1002/jso.22018. View

Chiu W, Fang P, Lee Y, Wang Y, Su Y, Hu S . DNA Repair Protein Rad51 Induces Tumor Growth and Metastasis in Esophageal Squamous Cell Carcinoma via a p38/Akt-Dependent Pathway. Ann Surg Oncol. 2019; 27(6):2090-2101. DOI: 10.1245/s10434-019-08043-x. View

Chen Q, Cai D, Li M, Wu X . The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinoma. Oncol Rep. 2017; 38(2):767-774. PMC: 5561999. DOI: 10.3892/or.2017.5724. View

Qiao G, Wu Y, Yang X, Zhong W, Xie D, Guan X . High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer. 2005; 93(1):137-43. PMC: 2361489. DOI: 10.1038/sj.bjc.6602665. View

Choi E, Kim K . E2F1 facilitates DNA break repair by localizing to break sites and enhancing the expression of homologous recombination factors. Exp Mol Med. 2019; 51(9):1-12. PMC: 6802646. DOI: 10.1038/s12276-019-0307-2. View

Nagathihalli N, Nagaraju G . RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Biochim Biophys Acta. 2011; 1816(2):209-18. DOI: 10.1016/j.bbcan.2011.07.004. View

Nakanoko T, Saeki H, Morita M, Nakashima Y, Ando K, Oki E . Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2013; 21(2):597-604. PMC: 3929771. DOI: 10.1245/s10434-013-3220-2. View

10.

Klein H . The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst). 2008; 7(5):686-93. PMC: 2430071. DOI: 10.1016/j.dnarep.2007.12.008. View

11.

Hansen L, Lundin C, Spang-Thomsen M, Petersen L, Helleday T . The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer. 2003; 105(4):472-9. DOI: 10.1002/ijc.11106. View

12.

Jensen R, Carreira A, Kowalczykowski S . Purified human BRCA2 stimulates RAD51-mediated recombination. Nature. 2010; 467(7316):678-83. PMC: 2952063. DOI: 10.1038/nature09399. View

13.

Liu Q, Jiang H, Liu Z, Wang Y, Zhao M, Hao C . Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLoS One. 2011; 6(8):e23427. PMC: 3152570. DOI: 10.1371/journal.pone.0023427. View

14.

Alagpulinsa D, Ayyadevara S, Shmookler Reis R . A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin. Front Oncol. 2014; 4:289. PMC: 4214226. DOI: 10.3389/fonc.2014.00289. View

15.

San Filippo J, Sung P, Klein H . Mechanism of eukaryotic homologous recombination. Annu Rev Biochem. 2008; 77:229-57. DOI: 10.1146/annurev.biochem.77.061306.125255. View

16.

Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N . Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006; 22(6):719-729. DOI: 10.1016/j.molcel.2006.05.022. View

17.

Wang Y, Chen Y, Lo S, Chi T, Chen Y, Hu S . MRE11 promotes oral cancer progression through RUNX2/CXCR4/AKT/FOXA2 signaling in a nuclease-independent manner. Oncogene. 2021; 40(20):3510-3532. PMC: 8134045. DOI: 10.1038/s41388-021-01698-5. View

18.

Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S . Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer. 2000; 88(6):907-13. DOI: 10.1002/1097-0215(20001215)88:6<907::aid-ijc11>3.0.co;2-4. View

19.

Tsai M, Kuo Y, Chiu Y, Su Y, Lin Y . Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. J Pharmacol Exp Ther. 2010; 335(3):830-40. DOI: 10.1124/jpet.110.173146. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View